Camilo Colaco - Academia.edu (original) (raw)

Papers by Camilo Colaco

As cardiovascular disease is a major cause of death in the western world, it is important that we... more As cardiovascular disease is a major cause of death in the western world, it is important that we understand the pathogenesis of atherosclerosis. Oxidized LDL is, scientifically, the major risk factor. This text explains what glycation is and how it could lead to the oxidization of LDL. It also summarizes the data on dietary sugars as risk factors and on diabetics as an experimental model for atherosclerosis.

Springer eBooks, 1994

Trehalose, a non-toxic disaccharide of glucose, is responsible for the remarkable survival of a g... more Trehalose, a non-toxic disaccharide of glucose, is responsible for the remarkable survival of a group of inconspicuous and little known desert organisms, called cryptobionts, which can desiccate totally during drought and yet recover completely when rehydrated. Our recent work has shown that this protection against desiccation damage can be reproduced in vitro when biomolecules are dried in the presence of this simple sugar. Trehalose drying technology has been utilised in a number of health care, pharmaceutical and biotechnological applications, where it has enabled the development of novel, robust and versatile formats.

Cell Biology International Reports, Sep 1, 1990

Clinical science. Supplement (1979), Dec 1, 1987

Vaccine, Apr 1, 2014

Background: The development of a vaccine against the human gastric pathogen Helicobacter pylori, ... more Background: The development of a vaccine against the human gastric pathogen Helicobacter pylori, the main causative agent of gastric adenocarcinoma, has been hampered by a number of issues, including the lack of a mucosal adjuvant for use in humans. Heat shock proteins (Hsp), highly conserved molecules expressed by both bacteria and mammalian species, possess a range of functions, including acting as chaperones for cellular proteins and the ability to activate innate immune receptors. Hsp complex (HspC) vaccines, containing Hsp derived from pathogenic bacteria, are immunostimulatory without addition of an exogenous adjuvant and can induce immunity against their chaperoned proteins. In this study we explored in mice the potential utility of a H. pylori HspC vaccine. Results: Vaccination with H. pylori HspC, by either the subcutaneous or respiratory mucosal route, induced a strong antibody response, elevated gastric cytokine levels and significant protection against subsequent live challenge with this pathogen. The level of protection induced by non-adjuvanted HspC vaccine was equivalent to that which resulted from vaccination with adjuvanted vaccines. While protection induced by immunisation with adjuvanted vaccines was associated with the development of a moderate to severe atrophic gastritis, that induced by H. pylori HspC only resulted in a mild inflammatory response, despite an increase in pro-inflammatory gastric cytokines. This reduced gastritis correlated with an increase in IL-10 and IL-13 levels in the gastric tissues of HspC vaccinated, H. pylori challenged mice. Conclusions: H. pylori HspC vaccines have the potential to overcome some of the issues preventing the development of a human vaccine against this pathogen: HspC induced protective immunity against H. pylori without addition of an adjuvant and without the induction of a severe inflammatory response. However, complete protection was not obtained so further optimisation of this technology is needed if a human vaccine is to become a reality.

SHOWN methods to reduce or prevent aggregation of a wide variety of substances (PE colloids, red ... more SHOWN methods to reduce or prevent aggregation of a wide variety of substances (PE colloids, red blood cells, drugs) during freeze / thaw O Dehydration / Rehydration IN WHICH ADDS trehalose A SOLUTION OR SUSPENSION OF THE SUBSTANCE BEFORE FREEZING OR dewatering.

UN METODO PARA PRESERVAR SUSTANCIAS BIOLOGICAS DELICADAS O COMPUESTOS ORGANICOS (A) EN ESTADO SEC... more UN METODO PARA PRESERVAR SUSTANCIAS BIOLOGICAS DELICADAS O COMPUESTOS ORGANICOS (A) EN ESTADO SECO Y/O (B) A ELEVADAS TEMPERATURAS Y/O (C) BAJO IRRADIACION COMPRENDE INCORPORAR A UN SISTEMA QUE CONTIENE LAS SUSTANCIAS DICHAS O COMPONENTES, UN AZUCAR O UN DERIVADO DE ESTE ELEGIDO ENTRE (I) UN GLUCOSIDO NO REDUCIDO DE UN COMPUESTO POLIALCOHOLICO SELECCIONADO DE ENTRE ALCOHOLES DE AZUCAR Y OTRO POLIALCOHOLES NO RAMIFICADOS O (II) UN OLISACARIDO ELEGIDO ENTRE RAFINOSA, ESTAQUIOSA Y MELECITOSA.

Antibody is an important antiviral defence. However, it is considered to do little against human ... more Antibody is an important antiviral defence. However, it is considered to do little against human gamma-herpesviruses, which establish predominantly latent infections regulated by T cells. One limitation on analysing these infections has been that latency is already well-established at clinical presentation; early infection may still be accessible to antibody. Here, using murid herpesvirus-4 (MuHV-4), we tested the impact of adoptively transferred antibody on early gamma-herpesvirus infection. Immune sera and neutralizing and non-neutralizing monoclonal antibodies (mAbs) all reduced acute lytic MuHV-4 replication. The reductions, even by neutralizing mAbs, were largely or completely dependent on host IgG Fc receptors. Therefore, passive antibody can blunt acute gamma-herpesvirus lytic infection, and does this principally by IgG Fc-dependent functions rather than by neutralization.

Procede de preparation de formes galeniques solides consistant a: a) combiner des constituants co... more Procede de preparation de formes galeniques solides consistant a: a) combiner des constituants comprenant une quantite de trehalose suffisante pour agir en tant que diluant efficace dans les comprimes obtenus et une quantite d'un agent actif, de sorte que chaque forme galenique obtenue contient une dose efficace d'agent actif, ainsi qu'une dose de solvant aqueux suffisante pour assurer la suspension ou la dissolution du trehalose et de l'agent actif; b) traiter le produit obtenu a l'etape a) afin d'obtenir une poudre, des granules ou des microgranules comprenant un melange sensiblement homogene des constituants; c) creer des formes galeniques a partir de la poudre, des granules ou des microgranules, le traitement decrit a l'etape b) n'etant pas le procede de traitement S-1.

Proteine de fusion comprenant un polypeptide de liaison de recepteur Fc et un polypeptide antigen... more Proteine de fusion comprenant un polypeptide de liaison de recepteur Fc et un polypeptide antigenique, et eventuellement une sequence lien ou une partie d'articulation avec le polypeptide de liaison de recepteur Fc et le polypeptide antigenique, le premier de ces deux polypeptides comprenant generalement le domaine de constante CH2 d'une immoglobuline IgG humaine. Le second polypeptide peut etre un polypeptide quelconque qui induit une reponse immune. L'administration de cette proteine entraine une reponse de lymphocytaire T induite conter le polypeptide antigenique dans la proteine de fusion. On decrit aussi des procedes de traitement de maladie au moyen de telles proteines.

UN METODO PARA AUMENTAR LA ESTABILIDAD DE SUSTANCIAS BIOLOGICAS DURANTE LA DESHIDRATACION QUE CON... more UN METODO PARA AUMENTAR LA ESTABILIDAD DE SUSTANCIAS BIOLOGICAS DURANTE LA DESHIDRATACION QUE CONSISTE EN ANADIR UNA SOLUCION O SUSPENSION ACUOSA DE LAS SUSTANCIAS Y UN EXCIPIENTE DE CARBOHIDRATO EN UNA CANTIDAD SUFICIENTE COMO PARA ESTABILIZAR LAS SUSTANCIAS, INHIBIDORES DE LA REACCION DE MAILLARD EN UNA CANTIDAD EFECTIVA COMO PARA IMPEDIR SUSTANCIALMENTE LA CONDENSACION DE GRUPOS AMINO Y GRUPOS CARBONILO REACTIVOS Y DESHIDRATAR LA COMPOSICION RESULTANTE.

Des inhibiteurs de la reaction de Maillard sont utilises dans le traitement ou la prophylaxie des... more Des inhibiteurs de la reaction de Maillard sont utilises dans le traitement ou la prophylaxie des maladies amyloides, telles que la maladie d'Alzheimer. Des exemples de ces inhibiteurs sont notamment l'aminoguanidine et l'amphotericine B.

BioProcessing Journal, 2015

Vaccine, Jul 5, 2018

Streptococcus pneumoniae has multiple protein antigens on the surface in addition to the serotype... more Streptococcus pneumoniae has multiple protein antigens on the surface in addition to the serotype specific polysaccharide capsule antigen. Whilst the capsule antigen is the target of the polysaccharide vaccines, bacterial proteins can also act as targets for the immune system. PnuBioVax (PBV) is being developed as a multi-antigen, serotype-independent prophylactic vaccine against S. pneumoniae disease. In this study we have sought to elucidate the immune response to PBV in immunised rabbits. Sera from PBV immunised rabbits contained high levels of IgG antibodies to the PBV vaccine, and pneumococcal antigens PspA, Ply, PsaA and PiuA which are components of PBV, when compared with control sera. The PBV sera supported killing of the vaccine strain TIGR4 in an opsonophagocytic killing assay and heterologous strains 6B, 19F and 15B. In addition, incubation in PBV sera led to agglutination of several strains of pneumococci, inhibition of Ply-mediated lysis of erythrocytes and reduced bact...

The invention relates to compositions with increased bioavailability administration to mucosal me... more The invention relates to compositions with increased bioavailability administration to mucosal membranes preferably comprise powdered, A MIXTURE OF AN INTIMATE effective amount of bioactive agent A hydrophobically and a carbohydrate derivative. The compositions also may contain a surface active agent, PREFERABLY FOR RELEASE IN OR YOUR EYE gastrointestinal mucosa LIBERATION.

As cardiovascular disease is a major cause of death in the western world, it is important that we... more As cardiovascular disease is a major cause of death in the western world, it is important that we understand the pathogenesis of atherosclerosis. Oxidized LDL is, scientifically, the major risk factor. This text explains what glycation is and how it could lead to the oxidization of LDL. It also summarizes the data on dietary sugars as risk factors and on diabetics as an experimental model for atherosclerosis.

Springer eBooks, 1994

Trehalose, a non-toxic disaccharide of glucose, is responsible for the remarkable survival of a g... more Trehalose, a non-toxic disaccharide of glucose, is responsible for the remarkable survival of a group of inconspicuous and little known desert organisms, called cryptobionts, which can desiccate totally during drought and yet recover completely when rehydrated. Our recent work has shown that this protection against desiccation damage can be reproduced in vitro when biomolecules are dried in the presence of this simple sugar. Trehalose drying technology has been utilised in a number of health care, pharmaceutical and biotechnological applications, where it has enabled the development of novel, robust and versatile formats.

Cell Biology International Reports, Sep 1, 1990

Clinical science. Supplement (1979), Dec 1, 1987

Vaccine, Apr 1, 2014

Background: The development of a vaccine against the human gastric pathogen Helicobacter pylori, ... more Background: The development of a vaccine against the human gastric pathogen Helicobacter pylori, the main causative agent of gastric adenocarcinoma, has been hampered by a number of issues, including the lack of a mucosal adjuvant for use in humans. Heat shock proteins (Hsp), highly conserved molecules expressed by both bacteria and mammalian species, possess a range of functions, including acting as chaperones for cellular proteins and the ability to activate innate immune receptors. Hsp complex (HspC) vaccines, containing Hsp derived from pathogenic bacteria, are immunostimulatory without addition of an exogenous adjuvant and can induce immunity against their chaperoned proteins. In this study we explored in mice the potential utility of a H. pylori HspC vaccine. Results: Vaccination with H. pylori HspC, by either the subcutaneous or respiratory mucosal route, induced a strong antibody response, elevated gastric cytokine levels and significant protection against subsequent live challenge with this pathogen. The level of protection induced by non-adjuvanted HspC vaccine was equivalent to that which resulted from vaccination with adjuvanted vaccines. While protection induced by immunisation with adjuvanted vaccines was associated with the development of a moderate to severe atrophic gastritis, that induced by H. pylori HspC only resulted in a mild inflammatory response, despite an increase in pro-inflammatory gastric cytokines. This reduced gastritis correlated with an increase in IL-10 and IL-13 levels in the gastric tissues of HspC vaccinated, H. pylori challenged mice. Conclusions: H. pylori HspC vaccines have the potential to overcome some of the issues preventing the development of a human vaccine against this pathogen: HspC induced protective immunity against H. pylori without addition of an adjuvant and without the induction of a severe inflammatory response. However, complete protection was not obtained so further optimisation of this technology is needed if a human vaccine is to become a reality.

SHOWN methods to reduce or prevent aggregation of a wide variety of substances (PE colloids, red ... more SHOWN methods to reduce or prevent aggregation of a wide variety of substances (PE colloids, red blood cells, drugs) during freeze / thaw O Dehydration / Rehydration IN WHICH ADDS trehalose A SOLUTION OR SUSPENSION OF THE SUBSTANCE BEFORE FREEZING OR dewatering.

UN METODO PARA PRESERVAR SUSTANCIAS BIOLOGICAS DELICADAS O COMPUESTOS ORGANICOS (A) EN ESTADO SEC... more UN METODO PARA PRESERVAR SUSTANCIAS BIOLOGICAS DELICADAS O COMPUESTOS ORGANICOS (A) EN ESTADO SECO Y/O (B) A ELEVADAS TEMPERATURAS Y/O (C) BAJO IRRADIACION COMPRENDE INCORPORAR A UN SISTEMA QUE CONTIENE LAS SUSTANCIAS DICHAS O COMPONENTES, UN AZUCAR O UN DERIVADO DE ESTE ELEGIDO ENTRE (I) UN GLUCOSIDO NO REDUCIDO DE UN COMPUESTO POLIALCOHOLICO SELECCIONADO DE ENTRE ALCOHOLES DE AZUCAR Y OTRO POLIALCOHOLES NO RAMIFICADOS O (II) UN OLISACARIDO ELEGIDO ENTRE RAFINOSA, ESTAQUIOSA Y MELECITOSA.

Antibody is an important antiviral defence. However, it is considered to do little against human ... more Antibody is an important antiviral defence. However, it is considered to do little against human gamma-herpesviruses, which establish predominantly latent infections regulated by T cells. One limitation on analysing these infections has been that latency is already well-established at clinical presentation; early infection may still be accessible to antibody. Here, using murid herpesvirus-4 (MuHV-4), we tested the impact of adoptively transferred antibody on early gamma-herpesvirus infection. Immune sera and neutralizing and non-neutralizing monoclonal antibodies (mAbs) all reduced acute lytic MuHV-4 replication. The reductions, even by neutralizing mAbs, were largely or completely dependent on host IgG Fc receptors. Therefore, passive antibody can blunt acute gamma-herpesvirus lytic infection, and does this principally by IgG Fc-dependent functions rather than by neutralization.

Procede de preparation de formes galeniques solides consistant a: a) combiner des constituants co... more Procede de preparation de formes galeniques solides consistant a: a) combiner des constituants comprenant une quantite de trehalose suffisante pour agir en tant que diluant efficace dans les comprimes obtenus et une quantite d'un agent actif, de sorte que chaque forme galenique obtenue contient une dose efficace d'agent actif, ainsi qu'une dose de solvant aqueux suffisante pour assurer la suspension ou la dissolution du trehalose et de l'agent actif; b) traiter le produit obtenu a l'etape a) afin d'obtenir une poudre, des granules ou des microgranules comprenant un melange sensiblement homogene des constituants; c) creer des formes galeniques a partir de la poudre, des granules ou des microgranules, le traitement decrit a l'etape b) n'etant pas le procede de traitement S-1.

Proteine de fusion comprenant un polypeptide de liaison de recepteur Fc et un polypeptide antigen... more Proteine de fusion comprenant un polypeptide de liaison de recepteur Fc et un polypeptide antigenique, et eventuellement une sequence lien ou une partie d'articulation avec le polypeptide de liaison de recepteur Fc et le polypeptide antigenique, le premier de ces deux polypeptides comprenant generalement le domaine de constante CH2 d'une immoglobuline IgG humaine. Le second polypeptide peut etre un polypeptide quelconque qui induit une reponse immune. L'administration de cette proteine entraine une reponse de lymphocytaire T induite conter le polypeptide antigenique dans la proteine de fusion. On decrit aussi des procedes de traitement de maladie au moyen de telles proteines.

UN METODO PARA AUMENTAR LA ESTABILIDAD DE SUSTANCIAS BIOLOGICAS DURANTE LA DESHIDRATACION QUE CON... more UN METODO PARA AUMENTAR LA ESTABILIDAD DE SUSTANCIAS BIOLOGICAS DURANTE LA DESHIDRATACION QUE CONSISTE EN ANADIR UNA SOLUCION O SUSPENSION ACUOSA DE LAS SUSTANCIAS Y UN EXCIPIENTE DE CARBOHIDRATO EN UNA CANTIDAD SUFICIENTE COMO PARA ESTABILIZAR LAS SUSTANCIAS, INHIBIDORES DE LA REACCION DE MAILLARD EN UNA CANTIDAD EFECTIVA COMO PARA IMPEDIR SUSTANCIALMENTE LA CONDENSACION DE GRUPOS AMINO Y GRUPOS CARBONILO REACTIVOS Y DESHIDRATAR LA COMPOSICION RESULTANTE.

Des inhibiteurs de la reaction de Maillard sont utilises dans le traitement ou la prophylaxie des... more Des inhibiteurs de la reaction de Maillard sont utilises dans le traitement ou la prophylaxie des maladies amyloides, telles que la maladie d'Alzheimer. Des exemples de ces inhibiteurs sont notamment l'aminoguanidine et l'amphotericine B.

BioProcessing Journal, 2015

Vaccine, Jul 5, 2018

Streptococcus pneumoniae has multiple protein antigens on the surface in addition to the serotype... more Streptococcus pneumoniae has multiple protein antigens on the surface in addition to the serotype specific polysaccharide capsule antigen. Whilst the capsule antigen is the target of the polysaccharide vaccines, bacterial proteins can also act as targets for the immune system. PnuBioVax (PBV) is being developed as a multi-antigen, serotype-independent prophylactic vaccine against S. pneumoniae disease. In this study we have sought to elucidate the immune response to PBV in immunised rabbits. Sera from PBV immunised rabbits contained high levels of IgG antibodies to the PBV vaccine, and pneumococcal antigens PspA, Ply, PsaA and PiuA which are components of PBV, when compared with control sera. The PBV sera supported killing of the vaccine strain TIGR4 in an opsonophagocytic killing assay and heterologous strains 6B, 19F and 15B. In addition, incubation in PBV sera led to agglutination of several strains of pneumococci, inhibition of Ply-mediated lysis of erythrocytes and reduced bact...

The invention relates to compositions with increased bioavailability administration to mucosal me... more The invention relates to compositions with increased bioavailability administration to mucosal membranes preferably comprise powdered, A MIXTURE OF AN INTIMATE effective amount of bioactive agent A hydrophobically and a carbohydrate derivative. The compositions also may contain a surface active agent, PREFERABLY FOR RELEASE IN OR YOUR EYE gastrointestinal mucosa LIBERATION.